September 2017 In a clinical trial, N-acetylcysteine did not help adults reduce their cannabis use, despite having been effective for adolescents in a previous trial. The results indicated that if adults are able to benefit from the medication, they will likely require a different treatment regimen than adolescents.
This study found that HIV-1 could be eliminated in mice using a combination of two antiviral technologies—long-acting viral reservoir–targeted antiretroviral therapy and CRISPR/Cas-9 gene editing. HIV was undetectable in 9 out of 23 mice that received the combination treatment. HIV was not eliminated in any of the mice that were given either treatment alone.
Treatment for alcohol and opioid use disorders (AOUD) is feasible in primary care settings, but ongoing funding to support organizational capacity is critical for sustaining such programs.
Several effective medications are now available for treating opioid use disorder but many patients who could benefit do not receive them. Some patients who receive the medications face challenges to staying in treatment.
In this international trial, participants who received the intervention engaged in HIV treatment, achieved viral suppression at higher rates, and died at half the rate of participants in a control group.
Interim treatment with buprenorphine significantly improved the psychiatric symptoms of people awaiting comprehensive treatment for opioid use disorder (OUD). Buprenorphine treatment, even without concurrent psychosocial counseling, may help patients with no, or delayed, access to comprehensive OUD treatment.
About 1 in 20 patients treated for a nonfatal opioid overdose in an emergency department died within 1 year of their visit, many within 2 days. Two-thirds of these deaths were directly attributed to subsequent opioid-related overdoses.